Brain Tumor Drugs Global Market Report 2025

Brain tumor drugs are medications utilized in the treatment of brain tumors, employing a range of approaches including chemotherapy, hormone therapies, anticonvulsants, and painkillers. While certain prescription drugs aim to manage symptoms during tumor treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.81 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the increasing prevalence of neurological disorders, increased healthcare expenditure, increased number of approvals for oncology (cancer) drugs, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to an increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs, and revised FDA regulations to facilitate biologics drug development. Major trends in the forecast period include investing in a combination of drugs for brain tumor treatment, adapting the use of phase zero clinical trials to improve efficacy, use of technology for drug delivery that improves the efficacy of the drug, focusing on the expansion of cell and gene therapy, and carrying out strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In September 2024, Stryker Corporation, a U.S.-based medical technology company focused on providing products and services to enhance healthcare outcomes, acquired NICO Corporation for an undisclosed amount. This acquisition aims to strengthen Stryker Corporation's minimally invasive neurosurgical solutions, especially for brain tumor removal and the treatment of intracerebral hemorrhage, thereby improving patient outcomes and fostering growth in its neurotechnology portfolio. NICO Corporation is a U.S.-based medical device company that specializes in developing minimally invasive neurosurgical technologies, particularly for the removal of brain tumors.

Major companies operating in the brain tumor drugs market include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratorios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2024. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Brain Tumor Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for brain tumor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The brain tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
• 2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
• Subsegments:
• 1) By Temozolomide: Oral Formulation; Injectable Formulation
• 2) By Bevacizumab: Monoclonal Antibody Therapy; Combination Therapy With Chemotherapy
• 3) By Other Drugs: Carmustine; Lomustine; Etoposide; Irinotecan; Novantrone (Mitoxantrone)
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.